Day One Biopharmaceuticals, Inc.
DAWN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.22 | -0.36 | -0.14 | -0.20 |
| FCF Yield | -6.77% | -12.89% | -7.80% | -5.42% |
| EV / EBITDA | -12.32 | -4.53 | -9.35 | -10.47 |
| Quality | ||||
| ROIC | -39.21% | -59.39% | -40.98% | -25.83% |
| Gross Margin | 95.98% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.82 | 0.78 | 0.77 | 0.67 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 46.51% | -36.56% | -94.38% | -316.31% |
| Safety | ||||
| Net Debt / EBITDA | 1.42 | 1.12 | 0.60 | 3.92 |
| Interest Coverage | 0.00 | 0.00 | -30.95 | -18,185.75 |
| Efficiency | ||||
| Inventory Turnover | 1.59 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 42.69 | -2,454.93 | -178.72 | -3,198.79 |